OVER-TIME II trial: design and rationale of a multicentre randomized study evaluating antithrombotic strategies in patients with acute coronary syndrome and coronary artery ectasia
European Heart Journal Open · 03.11.2026 · 6 (6)
DOI: 10.1093/ehjopen/oeag161 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Heart Journal Open, online erschienen am 30.09.2026. Verfasst von Edith Adame-Avilés und 14 weiteren Autor:innen. Beteiligte Einrichtung: Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Colonia Belisario Domínguez-Sección XVI, Tlalpan, 14080 Mex…. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Coronary artery ectasia (CAE) is characterized by diffuse coronary dilatation and increased thrombotic risk. In patients with acute coronary syndrome (ACS) and CAE, the optimal antithrombotic strategy remains unclear. Previously, an exploratory trial suggested that the combination of antiplatelet monotherapy plus oral anticoagulation may reduce ischaemic events without increasing bleeding risk compared to dual antiplatelet therapy (DAPT), although it was underpowered for definitive conclusions.
Aims
The aim of this study is to evaluate the efficacy and safety of antiplatelet monotherapy plus direct oral anticoagulation compared with DAPT in patients with ACS and culprit-vessel CAE in a multicentre randomized setting. Methods and results OVER-TIME II is a multicentre, multinational, randomized, open-label clinical trial with 1:1 allocation comparing acetylsalicylic acid 100 mg plus clopidogrel 75 mg vs. clopidogrel 75 mg plus rivaroxaban 15 mg daily. The study will include 326 patients with ACS and culprit-vessel CAE. Patients will be followed for 12 months. The co-primary efficacy endpoint is the time to first occurrence of a composite of cardiovascular death, non-fatal myocardial infarction, or repeat revascularization. The co-primary safety endpoint is the time to first occurrence of major or minor bleeding defined by the Bleeding Academic Research Consortium criteria. Secondary endpoints include individual components of the primary outcomes. Exploratory analyses will include genomic and transcriptomic profiling through DNA and RNA sampling to identify molecular signatures associated with thrombotic risk, treatment response, and clinical outcomes.
Conclusion
OVER-TIME II is designed to provide robust multicentre randomized evidence regarding the efficacy and safety of an anticoagulation-based strategy in patients with ACS and CAE, with the potential to contribute to future clinical research and guideline development. Registration NCT07511257. The trial is registered and publicly available on ClinicalTrials.gov and is currently actively recruiting patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Colonia Belisario Domínguez-Sección XVI, Tlalpan, 14080 Mexico City, Mexico.
- Plan of Combined Studies in Medicine (PECEM-MD/PhD), Faculty of Medicine, National Autonomous University of Mexico, Circuito Interior, Ciudad Universitaria, Coyoacán, 04510 Mexico City, Mexico.
- Centro de Estudios Clínicos Querétaro (CECLIQ), Querétaro 76000, Mexico.
- Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Colonia Belisario Domínguez-Sección XVI, Tlalpan, 14080 Mexico City, Mexico.
- Department of Interventional Cardiology, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Colonia Belisario Domínguez-Sección XVI, Tlalpan, 14080 Mexico City, Mexico.
- Laboratory of Cardiovascular Disease Genomics, National Institute of Genomic Medicine (INMEGEN), Periférico Sur No. 4809, Colonia Arenal Tepepan, Tlalpan, 14610 Mexico City, Mexico.
ORCID-Profile: Edith Adame-Avilés, Diego Araiza-Garaygordobil, Lissette García-Mena, Marco Alcocer-Gamba, Ana Cristina Maldonado-May, Ricardo Álvarez-Santana, José Raúl Nieto-Saucedo, Alejandro Iván Rojas-Arriaga, Rodrigo Gopar-Nieto, Jorge Daniel Sierra-Lara Martínez, Luis Alfonso Marroquín-Donday, Jesús Díaz-Marín, Leonor Jacobo-Albavera, María Alexandra Arias-Mendoza, Ajit S Mullasari
Zitieren
APA
Adame-Avilés, E., Araiza-Garaygordobil, D., García-Mena, L., Alcocer-Gamba, M., Maldonado-May, A. C., Álvarez-Santana, R., Nieto-Saucedo, J. R., Rojas-Arriaga, A. I., Gopar-Nieto, R., Sierra-Lara Martínez, J. D., Marroquín-Donday, L. A., Díaz-Marín, J., Jacobo-Albavera, L., Arias-Mendoza, M. A., & Mullasari, A. S. (2026). OVER-TIME II trial: design and rationale of a multicentre randomized study evaluating antithrombotic strategies in patients with acute coronary syndrome and coronary artery ectasia. European Heart Journal Open, 6(6). https://doi.org/10.1093/ehjopen/oeag161
Vancouver
Adame-Avilés E, Araiza-Garaygordobil D, García-Mena L, Alcocer-Gamba M, Maldonado-May AC, Álvarez-Santana R, et al. OVER-TIME II trial: design and rationale of a multicentre randomized study evaluating antithrombotic strategies in patients with acute coronary syndrome and coronary artery ectasia. European Heart Journal Open. 2026;6(6). doi:10.1093/ehjopen/oeag161
BibTeX
@article{AdameAvils2026,
author = {Adame-Avilés, Edith and Araiza-Garaygordobil, Diego and García-Mena, Lissette and Alcocer-Gamba, Marco and Maldonado-May, Ana Cristina and Álvarez-Santana, Ricardo and Nieto-Saucedo, José Raúl and Rojas-Arriaga, Alejandro Iván and Gopar-Nieto, Rodrigo and Sierra-Lara Martínez, Jorge Daniel and Marroquín-Donday, Luis Alfonso and Díaz-Marín, Jesús and Jacobo-Albavera, Leonor and Arias-Mendoza, María Alexandra and Mullasari, Ajit S},
title = {OVER-TIME II trial: design and rationale of a multicentre randomized study evaluating antithrombotic strategies in patients with acute coronary syndrome and coronary artery ectasia},
journal = {European Heart Journal Open},
year = {2026},
volume = {6},
number = {6},
doi = {10.1093/ehjopen/oeag161}
}
EUVIMED